PHARMACY POLICY STATEMENT
Ohio Medicaid

<table>
<thead>
<tr>
<th>DRUG NAME</th>
<th>Hemophilia and Other Clotting Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>BENEFIT TYPE</td>
<td>Medical</td>
</tr>
<tr>
<td>STATUS</td>
<td>Prior Authorization Required</td>
</tr>
</tbody>
</table>

Hemophilia is the most common severe hereditary hemorrhagic disorder. Both hemophilia A and B result from factor VIII and factor IX protein deficiency or dysfunction, respectively, and is characterized by prolonged and excessive bleeding after minor trauma or sometimes even spontaneously. Hemophilia A is more common than hemophilia B, representing 80–85% of the total hemophilia population.

Hemophilia and Other Clotting Disorders will be considered for coverage when the following criteria are met:

**Hemophilia A (Factor VIII Deficiency)**

For **initial** authorization:

1. Member has diagnosis of Hemophilia A (congenital Factor VIII deficiency); AND
2. For Jivi, member must be 12 years of age or older; AND
3. Medication is being prescribed by or in consultation with a hematologist; AND
4. Medication will be used for applicable situations listed in Table A or for Immune Tolerance Induction (ITI); AND
5. If request is for ITI, member must have severe hemophilia (factor level < 1%) with inhibitors (FVIII titre > 0.6 BU), and meet one of the following:
   a. Inhibitor titre < 10 BU/mL or titre fails to fall below 10 BU/mL within a year;
   b. Member is having severe or life-threatening bleeding;
   c. Member is having frequent bleeding and is being considered for bypassing agent prophylaxis; AND
6. If the request is for an extended half-life product and the member is 12 years of age or older, member must have a trial of Jivi. NOTE: Hemlibra is preferred for long-term prophylaxis.
7. If the request is for a standard half-life product, member must have a trial of Advate.
8. Member’s recent weight (kg), history of bleeds, number of **as needed doses** on hand, and inhibitor status have been provided for review.
9. **Dosage allowed:** Per package insert of individual drug. For ITI, dosages may range from 50 IU/kg three times weekly to 200 IU/kg daily depending on titre inhibitor levels.

*If all the above requirements are met, the medication will be approved for 30 days for perioperative management or 6 months for all other cases.*

Note: Approval will be for requested dosage, but no more than +/- 5-10% of prescribed assays.
For patients on prophylaxis: the number of **as needed doses** the patient has on hand will be
taken into consideration for treatment of acute bleeding episodes. A maximum of 5 as needed doses will be permitted at a time.

For **reauthorization**:

1. Member’s recent weight (kg), history of bleeds, number of as needed doses on hand, and inhibitor status have been provided for review; AND
2. Member has experienced positive clinical response from the use of factor; AND
3. If request is for a dosage increase, provider must submit a clinical rationale supported by chart notes; AND
4. For ITI, chart notes have been provided to show both of the following:
   a. Member continues to need ITI (e.g., inhibitor is detectable (> 0.6 BU), FVIII recovery < 66% of expected, FVIII half-life is < 7 hours); AND
   b. Member has shown at least 20% decline in the inhibitor titre level since the previous approval.

*If all the above requirements are met, the medication will be approved for an additional 6 months.*

### Hemophilia B (Factor IX Deficiency)

For **initial** authorization:

1. Member has diagnosis of Hemophilia B (congenital Factor IX deficiency); AND
2. For Ixinity, member must be 12 years of age or older; AND
3. For AlphaNine, member must be 17 years of age or older; AND
4. Medication is being prescribed by or in consultation with a hematologist; AND
5. Medication will be used for applicable situations listed in Table A or for Immune Tolerance Induction (ITI); AND
6. If request is for ITI, member must have inhibitors (FIX titre ≥ 0.3 BU) and prescriber must attest that benefit outweighs the risk of starting therapy; AND
7. Member’s recent weight (kg), history of bleeds, number of as needed doses on hand, and inhibitor status have been provided for review.
8. **Dosage allowed:** Per package insert of individual drug.

*If all the above requirements are met, the medication will be approved for 30 days for perioperative management or 6 months for all other cases.*

Note: Approval will be for requested dosage, but no more than +/- 5-10% of prescribed assays. For patients on prophylaxis: the number of as needed doses the patient has on hand will be taken into consideration for treatment of acute bleeding episodes. A maximum of 5 as needed doses will be permitted at a time.

For **reauthorization**:
1. Member’s recent weight (kg), history of bleeds, number of as needed doses on hand, and inhibitor status have been provided for review; AND
2. Member has experienced positive clinical response from the use of factor; AND
3. If request is for a dosage increase, provider must submit a clinical rationale supported by chart notes.

*If all the above requirements are met, the medication will be approved for an additional 6 months.*

### FEIBA (anti-inhibitor coagulant complex)

For **initial** authorization:

1. Member has a diagnosis of Hemophilia A or B with confirmed inhibitors (FVIII titre > 0.6 BU for hemophilia A or FIX titre ≥ 0.3 BU for hemophilia B); AND
2. Medication is being prescribed by or in consultation with a hematologist; AND
3. Medication will be used in one of the following situations:
   a. On-demand treatment of acute bleeding episodes;
   b. Perioperative management of bleeding;
   c. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes; AND
4. Member’s recent weight (kg), history of bleeds, and inhibitor status have been provided for review; AND
5. If member is using Hemlibra, must have a clinical reason why a recombinant activated factor VII (rFVIIa) such as NovoSevenRT or Sevenfact cannot be used.
6. **Dosage allowed:** Per package insert.

*If member meets all the requirements listed above, the medication will be approved for 30 days for perioperative management or 6 months for all other cases.*

Note: Approval will be for requested dosage, but no more than +/- 5-10% of prescribed assays.

For **reauthorization**:

1. Member’s recent weight (kg), history of bleeds, and inhibitor status have been provided for review; AND
2. Member has experienced positive clinical response from the use of factor; AND
3. If request is for a dosage increase, provider must submit a clinical rationale supported by chart notes.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 6 months.*

### Novoseven RT (Recombinant Factor VIIa)

For **initial** authorization:

1. Medication is being prescribed by or in consultation with a hematologist; AND
2. Medication is being used for the treatment of bleeding episodes OR perioperative management for one of the following diagnoses:
a. Hemophilia A or B with confirmed inhibitors (FVIII titre > 0.6 BU for hemophilia A or FIX titre ≥ 0.3 BU for hemophilia B);
b. Acquired hemophilia;
c. Congenital Factor VII (FVII) deficiency;
d. Glanzmann’s Thrombasthenia and platelet transfusion was either ineffective or contraindicated; AND

3. Member’s recent weight (kg), history of bleeds, and inhibitor status (if applicable) have been provided for review.

4. **Dosage allowed:** Per package insert.

*If member meets all the requirements listed above, the medication will be approved for 30 days for perioperative management or 6 months for all other cases.*

Note: Approval will be for requested dosage, but no more than +/- 5-10% of prescribed assays.

For **reauthorization:**

1. Member’s recent weight (kg), history of bleeds, and inhibitor status (if applicable) have been provided for review; AND
2. Member has experienced positive clinical response from the use of factor; AND
3. If request is for a dosage increase, provider must submit a clinical rationale supported by chart notes.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 6 months.*

---

**Sevenfact (Recombinant Factor VIIa)**

For **initial** authorization:

1. Member is 12 years of age or older; AND
2. Member has a diagnosis of Hemophilia A or B with confirmed inhibitors (FVIII titre > 0.6 BU for hemophilia A or FIX titre ≥ 0.3 BU for hemophilia B); AND
3. Medication is being prescribed by or in consultation with a hematologist; AND
4. Medication will be used as on-demand treatment of acute bleeding episodes; AND
5. Member’s recent weight (kg), history of bleeds, and inhibitor status have been provided for review.
6. **Dosage allowed:** Per package insert.

*If member meets all the requirements listed above, the medication will be approved for 6 months.*

Note: Approval will be for requested dosage, but no more than +/- 5-10% of prescribed assays.
For **reauthorization**:

1. Member’s recent weight (kg), history of bleeds, and inhibitor status have been provided for review;  
   AND
2. Member has experienced positive clinical response from the use of factor; AND
3. If request is for a dosage increase, provider must submit a clinical rationale supported by chart notes.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 6 months.*

**Hemlibra (emicizumab-kxwh)**

For **initial** authorization:

1. Member has diagnosis of Hemophilia A, with congenital factor VIII deficiency confirmed by blood coagulation testing; AND
2. Medication is being prescribed by or in consultation with a hematologist; AND
3. Member’s recent weight (kg), history of bleeds, and inhibitor status have been provided for review; AND
4. For member with factor VIII inhibitors, member must meet the following:  
   a. Chart notes with documented positive test for inhibitors (titer > 0.6 BU/mL [Bethesda unit per milliliter]); OR
5. For member without factor VIII inhibitors, member must have severe hemophilia A (Factor VIII level <1%); AND
6. Bypassing agents (e.g., Feiba, NovoSeven RT, Sevenfact) are discontinued the day before starting Hemlibra (if applicable); AND
7. Prophylactic use of factor replacements are discontinued after loading dose period is finished.

Note: Factor VIII may be used as on-demand therapy for breakthrough bleeding.

8. **Dosage allowed:** 3 mg/kg subQ once weekly for the first 4 weeks, followed by a maintenance dose of 1.5 mg/kg once every week, OR 3mg/kg once every 2 weeks, OR 6 mg/kg every 4 weeks.

*If member meets all the requirements listed above, the medication will be approved for 6 months.*

Note: Approval will be for the lowest number of vials to achieve requested dosage.

For **reauthorization**:

1. Member’s recent weight in kilograms is documented on medication prior authorization request;  
   AND
2. Chart notes have been provided showing that the member experienced a reduction in bleeding episodes compared to baseline.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 6 months.*
Von Willebrand Disease (VWD)

For **initial** authorization:

1. Member has a diagnosis of Von Willebrand Disease (VWD); AND
2. For Vonvendi, member must be 18 years of age or older; AND
3. Medication is being prescribed by or in consultation with a hematologist; AND
4. Medication will be used for applicable situations listed in Table A; AND
5. Member has severe vWD (except Alphanate) OR Member has mild or moderate vWD and the use of desmopressin is known or suspected to be ineffective or contraindicated; AND
6. Member’s recent weight (kg) and history of bleeds have been provided for review.

7. **Dosage allowed:** Per package insert of individual drug.

*If member meets all the requirements listed above, the medication will be approved for 30 days for perioperative management, or 6 months for all other cases.*

Note: Approval will be for requested dosage, but no more than +/- 5-10% of prescribed assays.

For **reauthorization**:

1. Member’s recent weight (kg) and history of bleeds have been provided for review; AND
2. Member has experienced positive clinical response from the use of factor; AND
3. If request is for a dosage increase, provider must submit a clinical rationale supported by chart notes.

*If member meets all the reauthorization requirements above, the medication will be approved for an additional 6 months.*

Miscellaneous Factors - (Obizur, Coagadex, Corifact, Tretten, Fibryga, RiaSTAP)

For **initial** authorization:

1. For Obizur, member must be 18 years of age or older with a baseline anti-porcine factor VIII inhibitor titer less than 20 BU; AND
2. Member has an FDA approved indication for use as listed in Table A; AND
3. Medication is being prescribed by or in consultation with a hematologist; AND
4. Member’s recent weight (kg), history of bleeds, and fibrinogen level (if available, Fibryga and RiaSTAP only) have been provided for review.
5. **Dosage allowed:** Per package insert.

*If member meets all the requirements listed above, the medication will be approved for 30 days for perioperative management or 6 months for all other cases.*

Note: Approval will be for requested dosage, but no more than +/- 5-10% of prescribed assays.

For **reauthorization**:

1. Member’s recent weight (kg) and history of bleeds have been provided for review; AND
2. Member has experienced positive clinical response from the use of factor; AND
3. If request is for a dosage increase, provider must submit a clinical rationale supported by chart notes.

_If member meets all the reauthorization requirements above, the medication will be approved for an additional 6 months._

### Anti-Clotting Products - (ATryn, Ceprotin)

For **initial** authorization:

1. Member has an FDA approved indication for use as listed in Table A; AND
2. Medication is being prescribed by or in consultation with a hematologist; AND
3. Member’s recent weight (kg) and chart notes supporting diagnosis have been provided for review.
4. **Dosage allowed:** Per package insert.

_If member meets all the requirements listed above, the medication will be approved for 6 months._

For **reauthorization**:

1. Member’s recent weight (kg) and documentation of positive clinical response have been submitted for review; AND
2. If request is for a dosage increase, provider must submit a clinical rationale supported by chart notes.

_If member meets all the reauthorization requirements above, the medication will be approved for an additional 6 months._

### Table A

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Drug Name</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant Factor VIII</td>
<td>Advate</td>
<td>• On-demand treatment and control of bleeding episodes</td>
</tr>
<tr>
<td>(Hemophilia A)</td>
<td></td>
<td>• Perioperative management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
</tr>
<tr>
<td></td>
<td>Afstyla</td>
<td>• On-demand treatment and control of bleeding episodes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Perioperative management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
</tr>
<tr>
<td></td>
<td>Kovaltry</td>
<td>• On-demand treatment and control of bleeding episodes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Perioperative management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
</tr>
<tr>
<td></td>
<td>Novoeight</td>
<td>• On-demand treatment and control of bleeding episodes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Perioperative management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
</tr>
<tr>
<td></td>
<td>Nuwiq</td>
<td>• On-demand treatment and control of bleeding episodes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Perioperative management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
</tr>
<tr>
<td>Product</td>
<td>Indications</td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Recombinate</td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Xyntha</td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Adynovate</td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Altuviiio</td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Eloctate</td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Esperoct</td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Jivi</td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Hemofil M</td>
<td>• Prevention and control of hemorrhagic episodes</td>
<td></td>
</tr>
<tr>
<td>Koate</td>
<td>• Prevention and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Hemlibra</td>
<td>• Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients with <strong>hemophilia A with or without factor VIII inhibitors</strong></td>
<td></td>
</tr>
<tr>
<td>Benefix</td>
<td><strong>Hemophilia B</strong> (congenital factor IX deficiency) for:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Ixinity</td>
<td>Adults and children ≥ 12 years of age with <strong>hemophilia B</strong> for:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adults with <strong>hemophilia B</strong> for:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Rixubis</td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td>Alprolix</td>
<td>• On-demand treatment and control of bleeding episodes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perioperative management</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Routine prophylaxis to reduce the frequency of bleeding episodes</td>
<td></td>
</tr>
</tbody>
</table>
| **Idelvion** | • On-demand treatment and control of bleeding episodes  
• Perioperative management  
• Routine prophylaxis to reduce the frequency of bleeding episodes |
| --- | --- |
| **Rebinyn** | • On-demand treatment and control of bleeding episodes  
• Perioperative management  
• Prevention and control of bleeding episodes |
| **Plasma-Derived Factor IX (Hemophilia B)** | **AlphaNine SD**  
• Prevention and control of bleeding episodes |
| **Factor IX Complex (Hemophilia B)** | **Profilnine SD**  
• Prevention and control of bleeding episodes |
| **Alphanate** | • Control and prevention of bleeding in patients with **hemophilia A**  
• Surgical and/or invasive procedures in adult and pediatric patients with **von Willebrand Disease** in whom desmopressin (DDAVP) is either ineffective or contraindicated. Not indicated for patients with severe VWD (Type 3) undergoing major surgery |
| **Humate-P** | **Hemophilia A**  
• Treatment and prevention of bleeding in adults  
**Von Willebrand disease**  
• Treatment of spontaneous and trauma-induced bleeding episodes  
• Perioperative management |
| **Wilate** | Children and adults with **von Willebrand disease** for:  
• On-demand treatment and control of bleeding episodes  
• Perioperative management  
Adolescents and adults with **hemophilia A** for:  
• On-demand treatment and control of bleeding episodes  
• Routine prophylaxis to reduce the frequency of bleeding episodes |
| **Vonvendi** | Adults with **von Willebrand disease** for:  
• On-demand treatment and control of bleeding episodes  
• Perioperative management  
• Routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease receiving on-demand therapy. |
| **Feiba** | **Hemophilia A and B with inhibitors** for:  
• On-demand treatment and control of bleeding episodes  
• Perioperative management  
• Routine prophylaxis to reduce the frequency of bleeding episodes |
| **NovoSeven RT** | • Treatment of bleeding episodes and peri-operative management in adults and children with **hemophilia A or B with inhibitors**  
• **Congenital Factor VII (FVII) deficiency**  
• **Glanzmann’s thrombasthenia** with refractoriness to platelet transfusions, with or without antibodies to platelets |
<table>
<thead>
<tr>
<th><strong>DATE</strong></th>
<th><strong>ACTION/DESCRIPTION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>12/15/2016</td>
<td>Policy issued.</td>
</tr>
<tr>
<td>06/12/2018</td>
<td>Policy placed in a new format. Initial authorization length increased to 6 months.</td>
</tr>
<tr>
<td>10/05/2018</td>
<td>New drug Jivi added to the list of antihemophilic agents.</td>
</tr>
<tr>
<td>08/06/2019</td>
<td>New drug Esperoct added to the list of antihemophilic agents.</td>
</tr>
</tbody>
</table>

**CareSource considers Hemophilia and Other Clotting Disorders not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**
10/19/2019  Policy updated to include Hemlibra criteria.

08/01/2020  Hemlibra criteria updated to include hematologist. Requirement changed for members without Factor VIII inhibitors to align better with current practice and clinical trials.

04/02/2021  Title updated to encompass all bleeding disorder products. Table A created for all products, indications, and J codes. Added separate criteria set for hemophilia A, hemophilia B, Feiba, NovoSevenRT, Sevenfact, Von Willebrand Disease, miscellaneous factors, and anti-clotting products (previously only had one set of criteria for hemophilia factor replacement). Updated Hemlibra’s weight requirement, reauth criteria, and dosage allowed section. Added approval instruction note for the factors and Hemlibra. Updated initial approval duration for all agents.

09/13/2022  Annual Review. Transferred to new template. Updated references. Removed discontinued medications from policy (Helixate, Kogenate). Updated Table A indications (VonVendi). Added baseline titer requirements for Obizur.

04/10/2023  Added Altuviiio and as needed acute bleed dosing guidance for prophylaxis to hemophilia A. Changed name from bleeding disorder agents to hemophilia and other clotting disorders. Added trial of Jivi (for extended half-life products) and Advate (for standard half-life products) for hemophilia A. Added a note that Hemlibra is preferred for long-term prophylaxis for hemophilia A. Removed trial of factor products, clinical reason factors cannot be used or poor venous access for patients who are not using factor products with Hemlibra.

References:

47. Pipe S. Emicizumab subcutaneous dosing every 4 weeks is safe and efficacious in the control of bleeding in persons with haemophilia A with and without inhibitors – Results from the phase 3 HAVEN 4 study. Presented at the World Federation of Hemophilia World Congress in Glasgow, Scotland; May 20–24, 2018. WFH Oral Presentation.